The upcoming report from Regeneron (REGN) is expected to reveal quarterly earnings of $11.60 per share, indicating a decline of 2.2% compared to the year-ago period. Analysts forecast revenues of ...

Libtayo was the sixth PD-L/PD-L1 inhibitor to reach the market, starting out as a therapy for another skin cancer called cutaneous squamous cell carcinoma (CSCC), and the rarity of that disease ...

TD Cowen adjusted its outlook on Regeneron Pharmaceuticals, with analyst Tyler Van Buren revising the price target to $1,030 ...

Regeneron stock has trended bearishly since August, but growth in LIBTAYO and DUPIXENT offers a promising outlook, prompting a BUY rating. EYLEA HD's success mitigates biosimilar competition ...

Regeneron Pharmaceuticals, Inc. announced positive results from the phase 3 C-POST trial, which demonstrated that adjuvant treatment with PD-1 inhibitor Libtayo (cemiplimab) led to a statistically ...

Sanofi and Regeneron have reported new data for Libtayo that suggests the drug could be a contender. Overall survival (OS) was 22 months with the combination, compared to 13 months with chemo on ...

(RTTNews) - Regeneron Pharmaceuticals, Inc. (REGN) reported positive results from the Phase 3 C-POST trial, which showed that adjuvant treatment with PD-1 inhibitor Libtayo led to a statistically ...

Additionally, the success of Libtayo in the treatment of cutaneous squamous cell carcinoma further supports the optimistic outlook. These factors collectively contribute to the positive assessment ...

Regeneron is facing headwinds with one of its top-selling medicines. However, two of the company's other products are performing well. Short-term prospects look uncertain, but the long run looks ...